Chuang-ming Zheng

Cheongju-si, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome research in bladder cancer.

Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome research in bladder cancer.

Journal: Investigative and clinical urology

Published: December 31, 2024

Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment.

Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment.

Journal: International journal of molecular sciences

Published: August 21, 2024

A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer.

A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer.

Journal: European urology

Published: October 27, 2023

COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.

COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.

Journal: Investigative and clinical urology

Published: July 14, 2023

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.

Journal: Cancers

Published: January 09, 2023

Study on the use of Nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues [Cancer Genetics 268-269 (2022) 137-143].

Study on the use of Nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues [Cancer Genetics 268-269 (2022) 137-143].

Journal: Cancer genetics

Published: December 09, 2022

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.

Journal: International journal of molecular sciences

Published: October 25, 2022

Study on the use of Nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues.

Study on the use of Nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues.

Journal: Cancer genetics

Published: May 18, 2022

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.

Journal: Investigative and clinical urology

Published: December 30, 2021

Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.

Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.

Journal: Prostate international

Published: October 27, 2021

Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy.

Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy.

Journal: Urologic oncology

Published: October 19, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026